Titan Pharmaceuticals (NASDAQ:TTNP) has treated the first patient in a Phase 1/2 trial of its ropinirole implant intended for the treatment of signs and symptoms of idiopathic Parkinson’s disease (PD).
Ropinirole is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of PD symptoms and restless leg syndrome.
It is commonly used in conjunction with L-dopa to help control serious motor complications and dyskinesias that frequently occur in patients after several years of L-dopa treatment. Clinical studies have shown that these side effects are associated with fluctuating medication levels that occur with oral formulations.
Titan’s ropinirole implant, which was developed utilizing its ProNeura drug delivery technology, is designed for the long-term, continuous delivery of ropinirole HCL. Continuous delivery of ropinirole could potentially minimize the serious motor complications experienced by some patients on oral daily-dosed formulations of the medication.
“With more than 10 million people worldwide suffering from Parkinson’s disease, new and better treatments are needed and we look forward to further evaluating the potential of a ropinirole implant in this study,” Dr. Aaron Ellenbogen of the Michigan Institute of Neurological Disorders, and the principal investigator at the first trial site near Detroit, said in a statement..
The study, which is being conducted at three clinical research sites in the U.S., is an open-label, sequential, dose escalation study that will enroll approximately 20 subjects with idiopathic PD.
The primary objectives are to characterize the pharmacokinetic profile of the ropinirole implants, to evaluate their safety and tolerability, and to explore potential signals of efficacy using established disease-specific assessment scales. Patients on a stable dose of L-dopa plus oral ropinirole will have their oral ropinirole switched to ropinirole implants for three months of treatment.
Initial data from the first cohort of patients is expected in the first quarter of 2018, with study completion targeted for the end of 2018.
“We believe our ropinirole implant has the potential to offer patients substantial benefits over existing daily and more frequently dosed oral formulations of ropinirole, and we look forward to continuing to enroll subjects in this study,” said Kate Beebe, EVP and chief development officer of Titan.
